Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient

1 . A therapeutic agent for skin injuries, comprising a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient.

2 . The therapeutic agent according to claim 1 , wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

3 . The therapeutic agent according to claim 2 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

4 . The therapeutic agent according to claim 3 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

5 . The therapeutic agent according to claim 1 , containing the active ingredient in an amount of 0.001 mg to 100 mg per unit formulation.

6 . A skin regeneration accelerator, comprising a substance acting on the growth hormone secretagogue receptor, or a pharmaceutically acceptable salt thereof, as an active ingredient.

7 . The accelerator according to claim 6 , wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

8 . The accelerator according to claim 7 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

9 . The accelerator according to claim 8 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

10 . The accelerator according to claim 6 , containing the active ingredient in an amount of 0.001 mg to 100 mg per unit formulation.

11 . A method for accelerating proliferation of a cultured skin cell, using a substance acting on the growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient.

12 . The method according to claim 11 , wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

13 . The method according to claim 12 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

14 . The method according to claim 13 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

15 . The method according to claim 11 , wherein proliferation of the cultured skin cell is performed in a medium containing the active ingredient in an amount of 0.0000001 mg/mL to 0.1 mg/mL.

16 . A treatment method of skin injuries, comprising administration of a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient to a mammal requiring treatment of skin injuries.

17 . The method according to claim 16 , wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

18 . The method according to claim 17 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

19 . The method according to claim 18 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

20 . The method according to claim 16 , wherein the active ingredient is administered in an amount of 0.001 mg to 100 mg per administration.

21 . A method for accelerating skin regeneration, comprising administration of a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient to a mammal requiring acceleration of skin regeneration.

22 . The method according to claim 21 , wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

23 . The method according to claim 22 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

24 . The method according to claim 23 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

25 . The method according to claim 21 , wherein the active ingredient is administered in an amount of 0.001 mg to 100 mg per administration.

26 . Use of a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient for production of a pharmaceutical composition for treatment of skin injuries.

27 . The use according to claim 26 , wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

28 . The use according to claim 27 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

29 . The use according to claim 28 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

30 . The use according to claim 26 , wherein the pharmaceutical composition for treatment of skin injuries contains the active ingredient in an amount of 0.001 mg to 100 mg per unit formulation.

31 . Use of a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient for production of a pharmaceutical composition for acceleration of skin regeneration.

32 . The use according to claim 3 l, wherein the substance is a peptide selected from the group consisting of (i) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a third amino acid residue from the amino terminus is a modified amino acid residue in which fatty acid is introduced into the side chain of the amino acid residue and (ii) a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which one or several of 5 th to 28 th amino acids from the amino terminus are deleted, substituted and/or added, and the 3 rd amino acid residue from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain of the amino acid residue, or a pharmaceutically acceptable salt thereof.

33 . The use according to claim 32 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus is a modified amino acid residue having fatty acid introduced into the side chain hydroxyl group of the amino acid residue.

34 . The use according to claim 33 , wherein the substance is a peptide having an amino acid sequence represented by SEQ ID NO: 1, in which a serine residue at the 3 rd position from the amino terminus has a side chain hydroxyl group acylated with an n-octanoyl group.

35 . The use according to claim 31 , wherein the pharmaceutical composition for acceleration of skin regeneration contains the active ingredient in an amount of 0.001 mg to 100 mg per unit formulation.